Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

被引：4

作者：

Zinzani, Pier Luigi ^{[1
,2
]}

Salles, Gilles ^{[3
]}

Moskowitz, Alison J. ^{[3
]}

Santoro, Armando ^{[4
]}

Mehta, Amitkumar ^{[5
]}

Barr, Paul M. ^{[6
]}

Mehta-Shah, Neha ^{[7
]}

Collins, Graham P. ^{[8
]}

Ansell, Stephen M. ^{[9
]}

Brody, Joshua D. ^{[10
]}

Domingo-Domenech, Eva ^{[11
]}

Johnson, Nathalie A. ^{[12
]}

Cunningham, David ^{[13
]}

Ferrari, Silvia ^{[14
]}

Lisano, Julie ^{[15
]}

Krajewski, Jennifer ^{[16
]}

Wen, Rachael ^{[16
]}

Akyol, Alev ^{[16
]}

Crowe, Russell ^{[16
]}

Savage, Kerry J. ^{[17
]}

机构：

[1] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[2] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Humanitas Univ, IRCCS Humanitas Res Hosp, Rozzano Milan, Italy

[5] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA

[6] Univ Rochester, Dept Med, Rochester, NY USA

[7] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[8] Oxford Univ Hosp NHS Trust, Churchill Hosp, Dept Hematol, Oxford, England

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Icahn Sch Med Mt Sinai, New York, NY USA

[11] Hosp Duran & Reynals, Inst Catala Oncol, Inst Invest Biomed Bellvitge IDIBELL, Clin Hematol Dept, Barcelona, Spain

[12] Jewish Gen Hosp, Dept Med & Oncol, Montreal, PQ, Canada

[13] Royal Marsden Hosp, London, England

[14] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy

[15] Seagen Inc, Bothell, WA USA

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] BC Canc, Vancouver, BC, Canada

来源：

BLOOD ADVANCES | 2024年 / 8卷 / 10期

关键词：

MYCOSIS-FUNGOIDES; PHYSICIANS CHOICE; CD30; EXPRESSION; ALCANZA; HODGKIN;

D O I：

10.1182/bloodadvances.2023011030

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2400 / 2404

页数：5

共 23 条

[1]

Bachy E, 2022, J CLIN ONCOL, V40

[2] Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma [J].

Barta, Stefan K. ;

Zain, Jasmine ;

MacFarlane, Alexander W. ;

Smith, Sonali M. ;

Ruan, Jia ;

Fung, Henry C. ;

Tan, Carlyn R. ;

Yang, Yibin ;

Alpaugh, R. Katherine ;

Dulaimi, Essel ;

Ross, Eric A. ;

Campbell, Kerry S. ;

Khan, Nadia ;

Siddharta, Rawat ;

Fowler, Nathan H. ;

Fisher, Richard, I ;

Oki, Yasuhiro .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (06) :356-+

[3] Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression [J].

Bennani, N. Nora ;

Kim, Hyo Jin ;

Pederson, Levi D. ;

Atherton, Pamela J. ;

Micallef, Ivana N. ;

Thanarajasingam, Gita ;

Nowakowski, Grzegorz S. ;

Witzig, Thomas ;

Feldman, Andrew L. ;

Ansell, Stephen M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)

[4] Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases [J].

Benner, Marchina F. ;

Jansen, Patty M. ;

Vermeer, Maarten H. ;

Willemze, Rein .

BLOOD, 2012, 119 (07) :1643-1649

[5] Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels [J].

Bossard, Celine ;

Dobay, Maria Pamela ;

Parrens, Marie ;

Lamant, Laurence ;

Missiaglia, Edoardo ;

Haioun, Corinne ;

Martin, Antoine ;

Fabiani, Bettina ;

Delarue, Richard ;

Tournilhac, Olivier ;

Delorenzi, Mauro ;

Gaulard, Philippe ;

de Leval, Laurence .

BLOOD, 2014, 124 (19) :2983-2986

[6] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[7] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma [J].

Herrera, Alex F. ;

Moskowitz, Alison J. ;

Bartlett, Nancy L. ;

Vose, Julie M. ;

Ramchandren, Radhakrishnan ;

Feldman, Tatyana A. ;

LaCasce, Ann S. ;

Ansell, Stephen M. ;

Moskowitz, Craig H. ;

Fenton, Keenan ;

Ogden, Carol Anne ;

Taft, David ;

Zhang, Qu ;

Kato, Kazunobu ;

Campbell, Mary ;

Advani, Ranjana H. .

BLOOD, 2018, 131 (11) :1183-1194

[8] The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma [J].

Horwitz, S. ;

O'Connor, O. A. ;

Pro, B. ;

Trumper, L. ;

Iyer, S. ;

Advani, R. ;

Bartlett, N. L. ;

Christensen, J. H. ;

Morschhauser, F. ;

Domingo-Domenech, E. ;

Rossi, G. ;

Kim, W. S. ;

Feldman, T. ;

Menne, T. ;

Belada, D. ;

Illes, A. ;

Tobinai, K. ;

Tsukasaki, K. ;

Yeh, S-P ;

Shustov, A. ;

Huettmann, A. ;

Savage, K. J. ;

Yuen, S. ;

Zinzani, P. L. ;

Miao, H. ;

Bunn, V ;

Fenton, K. ;

Fanale, M. ;

Puhlmann, M. ;

Illidge, T. .

ANNALS OF ONCOLOGY, 2022, 33 (03) :288-298

[9] Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data [J].

Horwitz, Steven M. ;

Scarisbrick, Julia J. ;

Dummer, Reinhard ;

Whittaker, Sean ;

Duvic, Madeleine ;

Kim, Youn H. ;

Quaglino, Pietro ;

Zinzani, Pier Luigi ;

Bechter, Oliver ;

Eradat, Herbert ;

Pinter-Brown, Lauren ;

Akilov, Oleg E. ;

Geskin, Larisa ;

Sanches, Jose A. ;

Ortiz-Romero, Pablo L. ;

Weichenthal, Michael ;

Fisher, David C. ;

Walewski, Jan ;

Trotman, Judith ;

Taylor, Kerry ;

Dalle, Stephane ;

Stadler, Rudolf ;

Lisano, Julie ;

Bunn, Veronica ;

Little, Meredith ;

Prince, H. Miles .

BLOOD ADVANCES, 2021, 5 (23) :5098-5106

[10] Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin [J].

Horwitz, Steven M. ;

Advani, Ranjana H. ;

Bartlett, Nancy L. ;

Jacobsen, Eric D. ;

Sharman, Jeff P. ;

O'Connor, Owen A. ;

Siddiqi, Tanya ;

Kennedy, Dana A. ;

Oki, Yasuhiro .

BLOOD, 2014, 123 (20) :3095-3100

← 1 2 3 →